Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Meningitis01:18

Viral Meningitis

165
Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
165
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

73
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
73
Arboviral Encephalitis01:25

Arboviral Encephalitis

52
Arboviral encephalitis refers to brain inflammation caused by arthropod-borne viruses, particularly those transmitted through mosquito vectors. Among these, West Nile virus (WNV), a member of the Flaviviridae family, is a significant public health concern. WNV is an enveloped, positive-sense, single-stranded RNA virus. Human infection typically begins when an infected mosquito introduces the virus into the dermis during feeding. The primary transmission cycle involves birds as amplifying hosts...
52
Vaccinations01:51

Vaccinations

54.7K
Overview
54.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.7K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.2K
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An immune competent mouse model for the characterization of recombinant measles vaccines.

Human vaccines & immunotherapeutics·2014
Same author

Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector.

Human vaccines & immunotherapeutics·2013
Same author

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Human vaccines & immunotherapeutics·2013
Same author

Applications and challenges of multivalent recombinant vaccines.

Human vaccines & immunotherapeutics·2012
Same author

Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma.

Vaccine·2009
Same author

Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses.

Vaccine·2009

Related Experiment Video

Updated: Apr 19, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Measles virus.

Hussein Y Naim1

  • 1a Life Sciences and Vaccines Consultant; Bern, Switzerland.

Human Vaccines & Immunotherapeutics
|December 9, 2014
PubMed
Summary
This summary is machine-generated.

Measles virus (MV) vaccines have reduced severe illness but not eradicated the disease. Novel molecular techniques now enable MV

Keywords:
SSPElive viral vaccinemeaslespathogenesisrecombinant vaccinesvaccineviral vectors

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.6K
Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus
09:08

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Published on: July 27, 2021

4.3K

Related Experiment Videos

Last Updated: Apr 19, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.6K
Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus
09:08

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Published on: July 27, 2021

4.3K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Measles virus (MV) historically caused significant morbidity and mortality.
  • Live attenuated MV vaccines reduced disease severity but failed to eradicate measles.
  • Continued measles outbreaks highlight the need for improved control strategies.

Purpose of the Study:

  • To review the advancements in measles virus (MV) research enabled by molecular biology.
  • To explore the potential of MV as a vector for novel vaccines and therapeutics.
  • To discuss the future prospects of MV-based recombinant strategies.

Main Methods:

  • Review of literature on MV biology, pathogenesis, and vaccine development.
  • Analysis of molecular techniques, including cDNA rescue of MV.
  • Evaluation of recombinant MV vector applications.

Main Results:

  • Molecular biology techniques have provided deep insights into MV biology and pathogenesis.
  • Novel vaccine candidates inducing immunity against measles and other pathogens have been developed.
  • MV shows promise as a platform for recombinant vaccines and therapeutic vectors.

Conclusions:

  • Despite vaccination, measles remains a global health concern.
  • Molecular advancements have opened new avenues for measles control.
  • Recombinant MV holds significant potential for future vaccine and therapeutic applications.